title: Subretinal fibrosis and uveitis: a spectral domain OCT study of its evolution and the minimal therapeutic effect of the off-label treatment with ranibizumab.
abstract: OBJECTIVE
  The subretinal fibrosis and uveitis (SFU) syndrome is a rare multifocal posterior uveitis characterized by progressive subretinal fibrosis and significant visual loss.
  
  
  METHODS
  Slit-lamp examination, dilated fundoscopy, fluorescein angiography, Spectral Domain-Optical Coherence Tomography (SD-OCT) and laboratory testing were employed.
  
  
  RESULTS
  A 52-year-old male presented with bilateral (best-corrected visual acuity: 2/10) visual loss. Clinical examination revealed bilateral anterior uveitis with posterior synechiae and posterior uveitis. Medical workup revealed no pathologic findings. Treatment included 1 gr intravenous prednisone followed by oral prednisone, immunosuppresive therapy and three ranibizumab injections in the right eye with no improvement. One year later, there was significant subretinal fibrosis. In the second year follow-up, the picture was slightly worse, with persisting bilateral macular edema and fibrosis.
  
  
  CONCLUSIONS
  This is the first SFU syndrome report monitored with SD-OCT. This novel imaging modality can localize the lesion level, guide the therapeutic approach and may prove helpful in assessing disease prognosis.
authors.affiliation: 2nd Department of Ophthalmology, Aristotle University of Thessaloniki, "Papageorgiou" General Hospital , Thessaloniki, Macedonia , Greece .
authors.forename: Chrysanthos
authors.initials: C
authors.lastname: Symeonidis
authors.forename: Anna
authors.initials: A
authors.lastname: Dastiridou
authors.forename: Vasilis
authors.initials: V
authors.lastname: Konidaris
authors.forename: Periklis
authors.initials: P
authors.lastname: Brazitikos
authors.forename: Sofia
authors.initials: S
authors.lastname: Androudi
mesh_terms: D061067:Antibodies, Monoclonal, Humanized / Q000008:administration & dosage*; D004305:Dose-Response Relationship, Drug; D005451:Fluorescein Angiography; D005654:Fundus Oculi; D006801:Humans; D008297:Male; D008875:Middle Aged; D056687:Off-Label Use; D000069579:Ranibizumab; D012160:Retina / Q000473:pathology*; D041623:Tomography, Optical Coherence / Q000379:methods*; D015866:Uveitis, Posterior / Q000175:diagnosis* / Q000188:drug therapy; D014792:Visual Acuity
chemical_list: D061067:Antibodies, Monoclonal, Humanized; D000069579:Ranibizumab
keywords: Choroiditis; pediatric; ranibizumab; spectral domain optical coherence tomography; subretinal fibrosis; uveitis